Cue Biopharma (NASDAQ:CUE) Lowered to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Cue Biopharma from “buy” to “hold,” while MarketBeat data shows the stock has an overall average rating of “sell.”
• Cue Biopharma shares opened at $34.20, up 10%, but the company reported a quarterly loss of $24.14 per share, substantially missing the $1.69 consensus estimate despite revenue of $7.88 million exceeding expectations.
• CEO Shao-Lee Lin sold 40,000 shares for approximately $1.08 million to cover tax withholding on vested equity awards; institutional investors own about 35.04% of the company.

Cue Biopharma (NASDAQ:CUE - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Saturday.

Separately, Weiss Ratings raised shares of Cue Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, May 18th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of "Sell".

Cue Biopharma Stock Up 10.0%

NASDAQ CUE opened at $34.20 on Friday. The firm has a market cap of $143.64 million, a price-to-earnings ratio of -6.12 and a beta of 2.47. The business has a 50-day moving average price of $29.50 and a 200-day moving average price of $147.28. Cue Biopharma has a twelve month low of $4.97 and a twelve month high of $45.50.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%. The business had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million.

Insider Activity at Cue Biopharma

In other Cue Biopharma news, CEO Shao-Lee Lin sold 40,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00. Following the completion of the transaction, the chief executive officer owned 724,253 shares of the company's stock, valued at $19,627,256.30. This represents a 5.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 14.56% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cue Biopharma

A number of hedge funds have recently made changes to their positions in CUE. GC Wealth Management RIA LLC boosted its stake in Cue Biopharma by 35.0% during the fourth quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company's stock valued at $1,415,000 after buying an additional 1,200,000 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in Cue Biopharma in the 3rd quarter worth approximately $439,000. Stifel Financial Corp increased its stake in Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company's stock worth $75,000 after acquiring an additional 50,000 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Cue Biopharma during the 3rd quarter worth approximately $62,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock worth $57,000 after acquiring an additional 73,000 shares in the last quarter. 35.04% of the stock is currently owned by hedge funds and other institutional investors.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source